Current evidence suggests that SGLT-2 inhibitors are more effective than both GLP-1 agonists and DPP-4 inhibitors in reducing the risk of hospitalization for heart failure (HHF) in T2DM (87,162 participants) [223], although the latter showed more potency in reducing HHF in T2DM than sulphonylureas (e.g., glibenclamide) and thiazolidinediones (glitazones) (127,555 patients in the meta-analysis) [224]. The gene discussed is DPP4; the disease is heart failure.